NewEdge Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

NewEdge Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-56	Closed	-$1.36K	–	4018
2025 Q1	$1.36K	Buy	56 +1	+2%	+$23	﹤0.01%	3582
2024 Q4	$1.15K	Buy	+55	New	+$1.18K	﹤0.01%	3543
2024 Q3	–	Sell	-70	Closed	-$1.08K	–	3840
2024 Q2	$1.08K	Hold	70	–	–	﹤0.01%	3455
2024 Q1	$1.12K	Hold	70	–	–	﹤0.01%	3477
2023 Q4	$1.18K	Sell	70 -3,196	-98%	-$43.7K	﹤0.01%	3438
2023 Q3	$38.2K	Buy	3,266 +226	+7%	+$3.02K	﹤0.01%	2177
2023 Q2	$40.9K	Sell	3,040 -18,626	-86%	-$268K	﹤0.01%	2153
2023 Q1	$359K	Sell	21,666 -8,392	-28%	-$138K	﹤0.01%	1283
2022 Q4	$331K	Buy	30,058 +1,223	+4%	+$18.8K	0.01%	955
2022 Q3	$370K	Buy	+28,835	New	+$342K	0.01%	1095
2022 Q2	–	Sell	-19,189	Closed	-$159K	–	1572
2022 Q1	$159K	Buy	+19,189	New	+$136K	﹤0.01%	1040

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NewEdge Advisors's CPRX Position: Q2 2025 in Review

NewEdge Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 56 shares — an estimated $1.36K sold.

NewEdge Advisors first reported a position in CPRX in Q1 2022 and held it in 11 quarters. The position peaked at $370K in Q3 2022. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

NewEdge Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 56 Catalyst Pharmaceutical shares in Q2 2025, an estimated $1.36K.
NewEdge Advisors first reported a position in Catalyst Pharmaceutical in Q1 2022 and held it in 11 quarters.
NewEdge Advisors's Catalyst Pharmaceutical position peaked at $370K in Q3 2022.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.